Fractional exhaled nitric oxide (FeNO): the future of asthma care?

Journal article

Asthma affects around one in 30 people and contributes to nearly half a million deaths worldwide every year. 1 It is estimated that asthma will cost the UK NHS 1.3 billion in 2023, including costs relating to primary care contacts and prescription of treatments for asthma. 2 Treatments that aim to minimise risk of acute asthma exacerbations focus on reducing airway inflammation. However, despite significant advancements and increasing expenditure on asthma medications, incidences of asthma-related admissions to hospital and deaths have not improved over the last decade. 3This issue highlights the need for a more personalised 'treatable traits' approach 4 whereby treatments are targeted and optimised based on an individual's underlying disease.

Authors: Wang, K; Stonham, C; Rutherford, C; Pavord, ID

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: Royal College of General Practitioners
• Journal: British Journal of General Practice
• Volume: 73
• Issue: 737
• Pages: 565-568
• Publication date: 2023-11-30
• DOI: 10.3399/bjgp23x735813
• EISSN: 1478-5242
• ISSN: 0960-1643
• Language: English
• Keywords: Exhalation; Medicine; Intensive care medicine; Exhaled nitric oxide; Spirometry; Internal medicine; Asthma; Anesthesia; Exhaled air; Toxicology; Nitric oxide